Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 8/20 | 1.00 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8995826 | 0.82 | XDH (0.68) | XDHKDM4EMEN1MAPTKMT2A | |
| SCHEMBL8677237 | 0.81 | XDH (0.68) | XDHKDM4ENPC1RAB9AMEN1 | |
| SCHEMBL10570830 | 0.79 | XDH (0.68) | XDHQTRT1FGFR1FGFR2NOS1 | |
| SCHEMBL10569841 | 0.79 | XDH (1.00) | XDHQTRT1FGFR1FGFR2NOS1 | |
| SCHEMBL2772506 | 0.76 | XDH (0.68) | XDHQTRT1FGFR1FGFR2NOS1 | |
| SCHEMBL13377864 | 0.76 | XDH (0.65) | XDHQTRT1FGFR1FGFR2NOS1 | |
| SCHEMBL2572687 | 0.76 | XDH (1.00) | XDHACMSDKDM4EMEN1ALDH1A1 | |
| SCHEMBL5383503 | 0.74 | MAPK13 (0.60) | XDHALDH1A1MAPTHPGD | |
| SCHEMBL5157870 | 0.74 | XDH (0.59) | XDHCDK5CDK5R1KDM4ENPC1 | |
| SCHEMBL1023569 | 0.73 | PIK3CG (0.70) | XDHQTRT1FGFR1FGFR2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 484 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206708-A1 | AN OXAZIRIDINE PLATFORM FOR TARGETING FUNCTIONAL ALLOSTERIC METHIONINE SITES | NOVARTIS AG (CH) | 2025-06-26 | — | — | US | claimed |
| EP-4538708-A1 | METHOD FOR IMPROVING EXPERIMENTAL FLUX OF INTERACTION BETWEEN COMPOUNDS AND PROTEINS | Southern University of Science and Technology (CN) | 2025-04-16 | — | — | EP | claimed |
| US-20250095772-A1 | METHOD FOR IMPROVING THROUGHPUT OF COMPOUND-PROTEIN INTERACTION EXPERIMENTS | SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2025-03-20 | — | — | US | claimed |
| CN-119628087-A | Power system optimal configuration method for promoting rural renewable energy consumption | 国网河南省电力公司经济技术研究院 | 2025-03-14 | — | — | CN | claimed |
| CN-119409758-A | ABPP-based anti-inflammatory 18 beta-glycyrrhetinic acid active molecular probe, synthesis and application | 武汉轻工大学 | 2025-02-11 | — | — | CN | claimed |
| EP-4499617-A1 | AN OXAZIRIDINE PLATFORM FOR TARGETING FUNCTIONAL ALLOSTERIC METHIONINE SITES | Novartis AG (CH) | 2025-02-05 | — | — | EP | claimed |
| CN-119078328-A | Polyolefin material with soft surface performance for laminating film, and preparation method and application thereof | 黄山永新股份有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-118257004-A | Method for screening molecular library from molecular library of DCL-ABPP | 华南理工大学 | 2024-06-28 | — | — | CN | claimed |
| WO-2024133743-A1 | METHOD FOR DIAGNOSING AND/OR CLASSIFYING THE SEVERITY OF A NEURODEGENERATIVE DISEASE | EM Scientific Limited (GB) | 2024-06-27 | — | — | WO | claimed |
| CN-117723760-A | Application of TMEM43 protein as fibrosis disease treatment target | 深圳大学 | 2024-03-19 | — | — | CN | claimed |
| CN-116648509-A | Methods and compositions for producing a recombinant component for food products and other products | 完美日股份有限公司 | 2023-08-25 | — | — | CN | claimed |
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | UNIVERSITAT AUTÒNOMA DE BARCELONA (ES) | 2023-05-11 | — | — | US | claimed |
| CN-116029157-A | Rural power system power supply configuration method for biomass power generation access and terminal equipment | 国网河南省电力公司经济技术研究院 | 2023-04-28 | — | — | CN | claimed |
| WO-2022104227-A9 | METHODS AND COMPOSITIONS FOR PRODUCING RECOMBINANT COMPONENTS FOR USE IN FOOD AND OTHER PRODUCTS | Perfect Day, Inc. (US) | 2023-04-20 | — | — | WO | claimed |
| EP-4125840-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | Som Innovation Biotech, S.A. (ES) | 2023-02-08 | — | — | EP | claimed |
| WO-2022104227-A1 | METHODS AND COMPOSITIONS FOR PRODUCING RECOMBINANT COMPONENTS FOR USE IN FOOD AND OTHER PRODUCTS | Perfect Day, Inc. (US) | 2022-05-19 | — | — | WO | claimed |
| WO-2021191417-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | SOM INNOVATION BIOTECH, S.A. (ES) | 2021-09-30 | — | — | WO | claimed |
| CN-101918566-A | By influencing the transfection results that innate immune system improves non-viral delivery system | BIONTEX LAB GMBH | 2010-12-15 | — | — | CN | claimed |
| EP-2212425-A2 | IMPROVEMENT OF TRANSFECTION RESULTS OF NON-VIRAL GENE DELIVERY SYSTEMS BY INFLUENCING THE CONGENITAL IMMUNE SYSTEM | Biontex Laboratories Gmbh (DE) | 2010-08-04 | — | — | EP | claimed |
| WO-2009065618-A2 | IMPROVEMENT OF TRANSFECTION RESULTS OF NON-VIRAL GENE DELIVERY SYSTEMS BY INFLUENCING THE CONGENITAL IMMUNE SYSTEM | BIONTEX LABORATORIES GMBH (DE) | 2009-05-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206708-A1 | AN OXAZIRIDINE PLATFORM FOR TARGETING FUNCTIONAL ALLOSTERIC METHIONINE SITES | MARCKS, PTMS, DMPK | XDH 4278/4885QTRT1 3618/4885FGFR1 2813/4885 |
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | SNCA, PARK7, PRNP | XDH 1449/4885QTRT1 3290/4885FGFR1 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.